Krahasoni metodat

	Provë e Përshtatshme e Randomizuar Klinike	Faza III e Provës Klinike
Fusha	Epidemiologji	Epidemiologji
Familja	Process / pipeline	Process / pipeline
Viti i origjinës	Late 1990s–2000s (widespread adoption post-2010)	1962 (Kefauver-Harris Amendment formalised phased drug development)
Krijuesi	Donald Berry and colleagues; formalized by FDA guidance in 2010 and 2019	FDA regulatory framework / ICH guidelines
Lloji	Experimental clinical trial design	Confirmatory randomised controlled trial
Burimi themelues	Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery, 5(1), 27–36.	Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185385
Emërtime të tjera	adaptive RCT, adaptive trial design, response-adaptive randomization trial, adaptive clinical trial	Phase 3 trial, confirmatory trial, pivotal trial, Phase III RCT
Të lidhura	6	6
Përmbledhja	An adaptive randomized clinical trial (adaptive RCT) is a prospective experimental study that uses pre-specified rules to modify one or more trial aspects — such as sample size, allocation ratios, or treatment arms — based on accumulating data collected during the trial itself, while maintaining statistical validity and integrity of the study.	A Phase III clinical trial is a large-scale, confirmatory randomised controlled trial designed to establish the efficacy and safety of an intervention in the target patient population before regulatory submission. It builds on the signal identified in Phase II, tests the intervention at its proposed dose under controlled conditions, and provides the primary evidence base for marketing authorisation or guideline adoption.